Market Overview

Biogen Announces New Data from Phase 3 Studies for Oral BG-12 Treatment for Multiple Sclerosis


Today Biogen Idec (NASDAQ: BIIB) announced new data from studies
evaluating oral BG-12 (dimethyl fumarate), which provide further
evidence supporting its strong clinical and radiological effects in
people with relapsing-remitting multiple sclerosis (RRMS) and reinforce
its favorable safety profile seen to date. These data were presented at
the 28th Congress of the European Committee for the Treatment
and Research of Multiple Sclerosis (ECTRIMS) in Lyon, France.

In a pre-specified analysis of integrated, or pooled, data from the
Phase 3 DEFINE and CONFIRM studies, dimethyl fumarate showed
statistically significant and clinically relevant effects in reducing
multiple sclerosis (MS) relapses and progression of disability, as well
as reductions in magnetic resonance imaging (MRI) measures of disease

See full press release

Posted-In: News Guidance Management Global


Related Articles (BIIB)

View Comments and Join the Discussion!